VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual | Dual antibody therapy in patients with systemic AL amyloidosis and cardiac involvement

Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, explores the results of a study evaluating concurrent dual monoclonal antibody treatment with daratumumab and NEOD001, an anti-amyloid antibody, in systemic amyloid light-chain (AL) amyloidosis with cardiac involvement. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter